Acacia Pharma Group 

Acacia Pharma Group Plc, a pharmaceutical company, focuses on the development and commercialization of hospital products for surgical and cancer patients in the United States and internationally. The company's lead product includes BAREMSIS, an intravenous formulation of amisulpride that has completed Phase III clinical trials for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also comprise APD403 that has completed Phase II clinical trials for the chemotherapy-induced nausea and vomiting treatment. The company was founded in 2007 and is based in Cambridge, the United Kingdom.